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Sir,
Simple method to reduce iatrogenic retinal trauma
during vitreous surgery
Posterior iatrogenic retinal trauma is a known
complication of vitreous surgery.1 We have had two cases
where the endoillumination pipe has caused direct
retinal trauma during epiretinal or internal-limiting
membrane peel. This is a delicate procedure that
demands intense concentration, often using a viewing
lens that greatly restricts the visible field.
To reduce the likelihood of trauma during this stage of
the procedure, we employed the simple use of a length of
butterfly tubing (Figures 1 and 2) threaded along the
illumination pipe to limit the depth to which the
illumination instrument can be inserted into the eye. This
butterfly tubing can be adjusted in length as required.
This has also been employed during a complex four-port
diabetic delamination surgery, where an assistant holds
the light pipe. The technique should be particularly
useful for trainee retinal surgeons.
Thankfully, we have not had any similar iatrogenic
breaks after employing this device.
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Sir,
Intravitreal triamcinolone acetonide as an adjunct in
the treatment of severe ocular toxoplasmosis
Treatment of ocular toxoplasmosis is highly
controversial. Results of such treatment depend
on host factors, such as age and immune status, as
well as on parasite factors.1 The use of corticosteroids
is even more debatable. Although most uveitis
specialists agree that corticosteroid therapy without
the concurrent use of antimicrobial agents can lead
to severe ocular tissue destruction, patients who did
well treated with corticosteroids alone have been
seen.1
Aggressive cases, such as the one reported by
Backhouse et al, have also been reported. It is important
to note, however, that clinical deterioration did not occur
immediately after the introduction of oral or intravitreal
corticosteroids. On the contrary, in these two
circumstances it appears that some improvement was
initially observed. Of note, the antimicrobial agent was
introduced 1 month following intravitreal triamcinolone
acetonide. Taking into account that clinical picture
worsening occurred only 2 weeks thereafter (6 weeks
following intraocular injection), the temporal
relationship strongly suggests that the intravitreal
triamcinolone acetonide injection was not directly related
to the outcome.
In our opinion, intravitreal corticosteroids should be
used with caution in active ocular toxoplasmosis.
Clinicians should avoid their use on recalcitrant, rapid
worsening cases or those with questionable diagnosis.
Intravitreal steroids without appropriate antimicrobial
drugs should also be discouraged. On the other hand,
there may be a role for them in patients with relatively
controlled infection, as those we reported previously on
this journal.2
References
1 Holland GN LX Edward Jackson Lecture Ocular
toxoplasmosis: a global reassessment Part II: disease
Figure 1 Butterfly tubing cut to desired length and threaded
along endoillumination pipe.





manifestations and management. Am J Ophthalmol 2004; 137:
1–17.
2 Aggio FB, Muccioli C, Belfort Jr R. Intravitreal triamcinolone
acetonide as an adjunct in the treatment of severe ocular
toxoplasmosis. Eye 2006; 20: 1080–1082.
FB Aggio, C Muccioli and R Belfort Jr
Department of Ophthalmology, The Vision
Institute, Federal University of Sa˜o Paulo, Sa˜o
Paulo, Brazil
E-mail: aggio@oftalmo.epm.br
Eye (2008) 22, 1200–1201; doi:10.1038/eye.2008.4;
published online 28 March 2008
Sir,
Intravitreal triamcinolone acetonide as an adjunct in
the treatment of severe ocular toxoplasmosis
We read with interest the paper by Aggio et al1 regarding
the possible beneficial use of intravitreal triamcinolone
acetonide (IVTA) injection for control of inflammation in
severe ocular toxoplasmosis. We would like to add a
word of caution to this approach.
Case report
A 49-year-old Caucasian male presented with a 5-day
history of reducing acuity with metamorphopsia in the
left eye. He was otherwise well. Snellen acuity was
recorded as 6/5 OD and CF OS. A yellow macular lesion
was seen surrounded by subretinal fluid. There was a
trace of vitreous activity and mild peripheral retinal
phlebitis. A fundus fluorescein angiogram revealed some
early hyperfluorescence with mild late leakage. Blood
investigations of FBC, CRP, U&Es, serum ACE,
rheumatoid factor, ANA, ANCA, VDRL, serum
electrophoresis as well as a Mantoux test and CXR were
all normal. A toxoplasma titre remained outstanding.
Three weeks following the first symptoms, oral
prednisolone was started at 75 mg and rapidly reduced
to 25 mg over 2 weeks. Partial resolution of the lesion was
observed. An urgent referral was then made to the
regional uveitis clinic.
In the uveitis clinic, 5 weeks following initial
symptoms, vision had slightly improved to 6/60. An
optical coherence topography scan (OCT) showed early
foveal scar formation (Figure 1). Peripheral retinal
phlebitis was confirmed. The working diagnosis was
idiopathic granulomatous panuveitis. A decision was
made to give 4 mg intravitreal triamcinolone to give the
best chance of visual recovery. One month later
azithromycin 500 mg was commenced as the toxoplasma
dye test was positive (1000 IU) as was toxoplasma IgM.
Two weeks later there was a dramatic worsening of
symptoms. A large white lesion occupied the area within
the macula arcades with overlying focal arteritis,
multiple small peripheral lesions, and increased vitreous
activity (Figure 2). Although the clinical findings were in
keeping with fulminant ocular toxoplasmosis, a sample
of anterior chamber fluid was sent for urgent polymerase
chain reaction for CMV, HSV, VZV, EBV, tuberculosis and
toxoplasmosis. All PCR results were negative except for a
positive toxoplasmosis result.
Despite repeated courses of azithromycin and
clindamycin, the inflammation continued to get worse
and obscured fundal examination. An MRI scan of the
orbits and brain showed involvement of the affected eye
only. After 6 weeks, a vitrectomy was undertaken to
remove the steroid and allow visualisation of the fundus.
Unfortunately areas of the retina had become necrotic,
with localised retinal detachment and so the eye was
indented with a plomb, lasered, and filled with silicone
oil. The retina remains flat but the left vision has
deteriorated to hand movements secondary to macula
subretinal fibrosis.
Comments
Cases of fulminant, uncontrolled ocular toxoplasmosis as
a result of a depot steroid injection have been reported,
some with concurrent antiparasitic cover.2–5 More
recently a poor outcome was reported in those patients
who received corticosteroids alone.6,7 Following a survey,
it was found that 9% of clinicians who responded had
used periocular corticosteroids in combination with oral
Figure 1 OCT scan of left macula showing a disrupted fovea.
Figure 2 Fundus photograph of left macula with an enlarging
area of focal and diffuse arteritis.
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